INTERSTITIAL NEPHRITIS WITH NEW IMMUNE CHECKPOINT INHIBITORS -PEMBROLIZUMAB

被引：0
|
作者：
Nagaraju, G. [1 ]
Clark, C. [1 ]
机构：
[1] Capital & Coast DHB, Wellington, New Zealand
来源：
NEPHROLOGY | 2018年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [21] IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
    Mitarai, Yuki
    Nakashima, Kazuhisa
    Fukunaga, Shohei
    Ishikawa, Noriyoshi
    Ito, Takafumi
    Tsubata, Yukari
    Isobe, Takeshi
    INTERNAL MEDICINE, 2022, 61 (13) : 2013 - 2017
  • [22] Interstitial Pneumonitis Associated with Immune Checkpoint Inhibitors Treatment in Cancer Patients
    Delaunay, Myriam
    Lusque, Amelie
    Meyer, Nicolas
    Michot, Jean-Marie
    Raimbourg, Judith
    Cadranel, Jacques
    Zalcman, Gerard
    Gounant, Valerie
    Moro-Sibilot, Denis
    Girard, Nicolas
    Thiberville, Luc
    Planchard, David
    Metivier, Anne Cecile
    Barlesi, Fabrice
    Dansin, Eric
    Perol, Maurice
    Pichon, Eric
    Gautschi, Oliver
    Martin, Fruh
    Collot, Samia
    Jaffro, Marion
    Prevot, Gregoire
    Milia-Baron, Julie
    Mazieres, Julien
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1292 - S1293
  • [23] IMMUNE CHECKPOINT INHIBITORS: NEW CHALLENGES FOR NEPHROLOGISTS
    Chuva, Teresa
    Maximino, Jose
    Henrique, Rui
    Paiva, Ana
    Loureiro, Alfredo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [24] Immune checkpoint inhibitors and neuropathy: A new dawn
    Vucic, Steve
    CLINICAL NEUROPHYSIOLOGY, 2019, 130 (08) : 1401 - 1402
  • [25] Update on New Therapies With Immune Checkpoint Inhibitors
    Peterson, Jennifer J.
    Steele-Moses, Susan K.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2016, 20 (04) : 405 - 410
  • [26] Omeprazole/pembrolizumab interactionAcute interstitial nephritis: case report
    Reactions Weekly, 2021, 1837 (1) : 544 - 544
  • [27] Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
    Barbee, Meagan S.
    Ogunniyi, Adebayo
    Horvat, Troy Z.
    Dang, Thu-Oanh
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (08) : 907 - 937
  • [28] Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
    Wong, Jeffrey Sum Lung
    Kwok, Gerry Gin Wai
    Tang, Vikki
    Li, Bryan Cho Wing
    Leung, Roland
    Chiu, Joanne
    Ma, Ka Wing
    She, Wong Hoi
    Tsang, Josephine
    Lo, Chung Mau
    Cheung, Tan To
    Yau, Thomas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [29] Interstitial fibrosis and tubular atrophy of immune checkpoint inhibitor-related interstitial nephritis associate mortality and kidney prognosis
    Matsubara, Takeshi
    Yamamoto, Shinya
    Kuwabara, Takashige
    Miyazawa, Shuma
    Miyasato, Yoshikazu
    Sawa, Naoki
    Sugiyama, Hitoshi
    Maruyama, Shoichi
    Mukoyama, Masashi
    Yanagita, Motoko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I680 - I680
  • [30] Interstitial fibrosis and tubular atrophy of immune checkpoint inhibitor-related interstitial nephritis associate mortality and kidney prognosis
    Matsubara, Takeshi
    Yamamoto, Shinya
    Kuwabara, Takashige
    Miyazawa, Shuma
    Miyasato, Yoshikazu
    Sawa, Naoki
    Sugiyama, Hitoshi
    Maruyama, Shoichi
    Mukoyama, Masashi
    Yanagita, Motoko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
12345